[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655636":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":21,"armGroups":22,"interventions":33,"overallOfficials":17,"centralContacts":43,"locations":17,"responsibleParty":49,"collaborators":17,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":17,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":17,"enrollmentInfo":61,"targetDuration":17,"studyType":64,"phases":17,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":74,"whyStopped":17,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":17},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Progression-free survival (PFS)","the time from initiation of treatment to disease progression or death.","Up to 2 years after treatment",[14],{"measure":15,"description":16,"timeFrame":12},"Overall survival (OS)","the time from initiation of treatment to death, loss to follow-up, or last follow-up.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Patients diagnosed with hepatocellular carcinoma who underwent diaphragm hydrodissectionassisted microwave ablation or surgical resection at our hospital. All patients were definitively diagnosed with hepatocellular carcinoma based on combined imaging and pathological findings.",[23,28],{"label":24,"type":17,"description":25,"interventionNames":26},"Hydrodissection-assisted microwave ablation cohort","Patients with hepatocellular carcinoma receiving hydrodissection-assisted microwave ablation under routine clinical care. No study-specific intervention will be assigned by researchers.",[27],"Procedure: Microwave Ablation Assisted by Diaphragm Hydrodissection",{"label":29,"type":17,"description":30,"interventionNames":31},"Surgical resection cohort","Patients with hepatocellular carcinoma receiving surgical resection under routine clinical care. No study-specific intervention will be assigned by researchers.",[32],"Procedure: Surgical Resection",[34,39],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":17},"PROCEDURE","Microwave Ablation Assisted by Diaphragm Hydrodissection","For subphrenic hepatocellular carcinoma treated with microwave ablation, ultrasound-guided injection of normal saline into the diaphragm is performed during ablation to establish a hydrodissection barrier and optimise lesion visualisation.",[24],{"type":35,"name":40,"description":41,"armGroupLabels":42,"otherNames":17},"Surgical Resection","Patients with subphrenic hepatocellular carcinoma who undergo surgical resection are managed according to clinical diagnostic and therapeutic standards for hepatocellular carcinoma.",[29],[44],{"name":45,"role":46,"phone":47,"phoneExt":17,"email":48},"dezhi Zhang Associate Chief Physician, MD","CONTACT","+8618186876068","dezhi@jlu.edu.cn",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Dezhi Zhang","Associate Chief Physician，Abdominal Ultrasound Department","100655636","efficacy-evaluation-of-microwave-ablation-assisted-by-diaphragm-hydrodissection-for-hepatocellular-carcinoma-and-comparative-analysis-with-surgical-100655636",false,"NCT07815054","Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical","Inclusion Criteria:Patients with Child-Pugh grade A or B liver function.Single hepatic lesion with a maximum diameter ≤ 5 cm.The lesion is located in the subphrenic region with a distance ≤ 10 mm from the right diaphragm.\n\nExclusion Criteria:Presence of extrahepatic metastasis or other concomitant malignant tumors.Presence of severe cardiac, pulmonary, or renal dysfunction.Platelet count \\\u003C 50×10⁹\u002FL with irreversible coagulation disorders. Patients with incomplete imaging or clinical medical data.","ALL","18 Years",{"count":62,"type":63},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical resection for hepatocellular carcinoma. The main questions it aims to answer are:\n\nIs hydrodissection-assisted microwave ablation safe and effective for treating hepatocellular carcinoma? How does the therapeutic effect of hydrodissection-assisted microwave ablation compare with surgical resection for hepatocellular carcinoma? Patients who receive either microwave ablation or surgical resection will Undergo a 2-year follow-up period.",[67],"Hepatocellular Carcinoma (HCC)",[69,70,71,72,73],"Hepatocellular Carcinoma","microwave ablation","Progression-Free Survival","Overall Survival","Diaphragm Hydrodissection","NOT_YET_RECRUITING","2026-09-07",{"date":77,"type":78},"2026-09-11","ACTUAL",{"date":80,"type":63},"2026-10-01",{"date":82,"type":63},"2029-09-30",{"name":5,"class":6}]